As of the last check during current-market session, the stock value of Longeveron Inc. (NASDAQ: LGVN) increased significantly on US charts, gaining by 49.17% to $2.70. The company's participation in a noteworthy event is responsible for this spike, which has a favorable effect on investor confidence.
- CEO's Address During the Emerging Growth Conference
- Progress In ELPIS II Clinical Trial
- Collaboration And Future Prospects
CEO's Address During the Emerging Growth Conference
On June 12, 2024, Mohamed Wa'el Hashad, the CEO and director of Longeveron (LGVN), gave the keynote speech at the 72nd Emerging Growth Conference. EmergingGrowth.com, a reputable independent small-cap media company, is hosting the conference. It has been highlighting companies with strong management teams, innovative products and services, and an intense focus on long-term growth across a range of growing industries.
Progress In ELPIS II Clinical Trial
In addition to the market activity, Longeveron successfully conducted an investigator meeting for ELPIS II, its ongoing Phase 2b clinical trial. This trial is evaluating Lomecel-B as a potential adjunct treatment for Hypoplastic Left Heart Syndrome (HLHS), a rare congenital heart defect in children.
The meeting, which gathered principal investigators and site staff from leading pediatric treatment institutions, focused on the trial's progress and operational strategies. Three nationally recognized pediatric cardiothoracic centers also participated as part of their preparation to join as investigative sites.
The initial data from ELPIS I demonstrated that infants treated with Lomecel-B had a 100% transplant-free survival rate up to five years of age, compared to a historical control data mortality rate of approximately 20%. ELPIS II aims to further assess the safety and efficacy of Lomecel-B in this patient population, with full enrollment expected by the end of 2024.
Collaboration And Future Prospects
Lomecel-B, the company's primary experimental treatment, is an adult human bone marrow-derived medicinal signaling cell therapy that is scalable, proprietary, and allogeneic. With funding from the National Institutes of Health (NIH), the ELPIS II experiment is being carried out in partnership with the National Heart, Lung, and Blood Institute (NHLBI) with the goal of enrolling 38 pediatric patients by the end of 2024. Building on the encouraging outcomes of ELPIS I, this trial highlights Lomecel-B's potential as a regenerative medical treatment for newborns with HLHS.
在本次市場交易會話的最新檢查中，納斯達克（NASDAQ: LGVN）的股票價值在美國圖表上顯著增長，上漲49.17%至2.7美元。公司參加了一個值得注意的活動，這導致了股票的飆升，對投資者信心產生了積極影響。
- CEO在新興成長會議上的講話
- ELPIS II臨床試驗的進展
- 合作與未來展望
CEO在新興成長會議上的講話
2024年6月12日，Longeveron（LGVN）的首席執行官兼董事Mohamed Wa'el Hashad在第72屆新興成長會議上發表了主旨演講。該會議由備受尊重的獨立小市值媒體公司EmergingGrowth.com主辦。該公司一直在突出表現出色的管理團隊、創新產品和服務以及對不斷髮展的行業進行長期關注的公司。
ELPIS II臨床試驗的進展
除了市場活動外，Longeveron還成功召開了ELPIS II調查員會議，這是其正在進行中的2b期臨床試驗。該試驗評估Lomecel-B作爲治療嬰兒先天性心臟缺陷的潛在輔助治療方案。
此次會議彙集了來自主要小兒科治療機構的主要調查員和現場工作人員，重點討論了試驗的進展和運營策略。此外，三個國家認可的小兒心胸中心還作爲調查站點的準備加入。
ELPIS I的初步數據表明，接受Lomecel-B治療的嬰兒在達到5歲之前有100%的無移植生存率，而歷史對照數據的死亡率約爲20%。ELPIS II旨在進一步評估Lomecel-B在這種患者群體中的安全性和有效性，預計到2024年底完成招募。
合作與未來展望
公司的主要實驗治療Lomecel-B是一種成人人類骨髓來源的醫藥信號細胞療法，可擴展、專有和異體。在國立衛生研究院（NIH）的資助下，ELPIS II試驗與國立心臟、肺和血液研究所（NHLBI）合作進行，旨在在2024年底之前招募38名小兒患者。建立在ELPIS I的令人鼓舞的結果基礎之上，這項試驗突顯了Lomecel-B作爲治療新生兒HLHS的再生醫學治療方法的潛力。
